Citations

Mayo Clinic

Showing 10 of 108523 citations.

Improved Outcomes in Metastatic Colon Cancer
Sargent, Daniel J. , Sargent, Daniel

JAMA Oncology | June 25, 2015 | Volume: 1 | Issue: 6 | Pages: 795

10.1001/jamaoncol.2015.1789 | PMID 26181004 Get It

Clinical features of Behçet’s disease: A retrospective chart review of 26 patients
Davari, Parastoo , Rogers, Roy S., Chan, Brian , Nagler, Travis H., Fazel, Nasim , Nagler, Travis

Journal of Dermatological Treatment | June 25, 2015 | Volume: 27 | Issue: 1 | Pages: 70-74

10.3109/09546634.2015.1054781 | PMID 26108444 Get It

Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls
Anderson, Lesley , James, Glen , Duncombe, Andrew , Scherber, Robyn M. , Dueck, Amylou C. , Vocht, Frank de , Mesa, Ruben, Scherber, Robyn, Dueck, A. C. , Mesa, Ruben A. , Clarke, Mike J , McMullin, Mary Frances , Anderson, Lesley A

American Journal of Hematology | June 25, 2015 | Volume: 90 | Issue: 10 | Pages: 864-870

10.1002/ajh.24098 | PMID 26113113 Get It

The myeloproliferative neoplasms (MPN) including polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis (PMF) are rare diseases contributing to significant morbidity. Symptom management is a prime treatment objective but current symptom assessment tools have not been validated compared to the general population. The MPN‐symptom assessment form (MPN‐SAF), a reliable and validated clinical tool to assess MPN symptom burden, was administered to MPN patients (n = 106) and, for the first time, population controls (n = 124) as part of a UK case–control study. Mean symptom scores were compared between patients and controls adjusting for potential confounders. Mean patient scores were compared to data collected by the Mayo Clinic, USA on 1,446 international MPN patients to determine patient group representativeness. MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (P < 0.05); fatigue was the most common symptom (92.4% and 78.1%, respectively). Female MPN patients suffered worse symptom burden than male patients (P < 0.001) and substantially worse burden than female controls (P < 0.001). Compared to the Mayo clinic patients, MPN‐UK patients reported similar symptom burden but lower satiety (P = 0.046). Patients with PMF reported the worst symptom burden (88.3%); significantly higher than PV patients (P < 0.001). For the first time we report quality of life was worse in MPN‐UK patients compared with controls (P < 0.001). Am. J. Hematol. 90:864–870, 2015. © 2015 Wiley Periodicals, Inc.
Estrogen actions in the nervous system
Cersósimo, María G. , Benarroch, Eduardo E.

Neurology | June 25, 2015 | Volume: 85 | Issue: 3 | Pages: 263-273

10.1212/wnl.0000000000001776 | PMID 26109716 Get It

Imaging evaluation of treated benign bone tumours
Dobson, Michael A., McDonald, Douglas J. , Wessell, Daniel E. , Friedman, Michael

Journal of Medical Imaging and Radiation Oncology | June 25, 2015 | Volume: 59 | Issue: 5 | Pages: 599-604

10.1111/1754-9485.12329 | PMID 26108970 Get It

SummaryA number of benign bone tumours can be treated with curettage and packing with either bone cement or graft. It is essential that the radiologist be familiar with both the normal and abnormal post‐operative imaging appearance of these treated tumours. Through the use of numerous imaging examples, we aim to provide a pictorial review of the expected post‐operative appearance of benign bone tumours treated with curettage and packing, as well as the imaging features of recurrence, the most common potential complication.
Osteoclast TGF-β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation
Weivoda, Megan , Ruan, Ming, Pederson, Larry, Hachfeld, Christine, Davey, Rachel A. , Zajac, Jeffrey D. , Khosla, Sundeep , Oursler, Merry Jo, Weivoda, Megan M, Westendorf, Jennifer J. , Khosla, Sundeep

Journal of Bone and Mineral Research | June 25, 2015 | Volume: 31 | Issue: 1 | Pages: 76-85

10.1002/jbmr.2586 | PMID 26108893 Get It

ABSTRACT Osteoblast-mediated bone formation is coupled to osteoclast-mediated bone resorption. These processes become uncoupled with age, leading to increased risk for debilitating fractures. Therefore, understanding how osteoblasts are recruited to sites of resorption is vital to treating age-related bone loss. Osteoclasts release and activate TGF-β from the bone matrix. Here we show that osteoclast-specific inhibition of TGF-β receptor signaling in mice results in osteopenia due to reduced osteoblast numbers with no significant impact on osteoclast numbers or activity. TGF-β induced osteoclast expression of Wnt1, a protein crucial to normal bone formation, and this response was blocked by impaired TGF-β receptor signaling. Osteoclasts in aged murine bones had lower TGF-β signaling and Wnt1 expression in vivo. Ex vivo stimulation of osteoclasts derived from young or old mouse bone marrow macrophages showed no difference in TGF-β–induced Wnt1 expression. However, young osteoclasts expressed reduced Wnt1 when cultured on aged mouse bone chips compared to young mouse bone chips, consistent with decreased skeletal TGF-β availability with age. Therefore, osteoclast responses to TGF-β are essential for coupling bone resorption to bone formation, and modulating this pathway may provide opportunities to treat age-related bone loss. © 2015 American Society for Bone and Mineral Research.
The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies
Beebe‐Dimmer, Jennifer , Hathcock, Matthew , Yee, Cecilia, Okoth, Linda A. , Ewing, Charles M., Isaacs, William B. , Cooney, Kathleen A. , Thibodeau, Stephen N.

Cancer Epidemiology, Biomarkers & Prevention | June 24, 2015 | Volume: 24 | Issue: 9 | Pages: 1366-1372

10.1158/1055-9965.epi-15-0247 | PMID 26108461 Get It

Abstract Background: A rare nonconservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer. DNA samples from male patients included in the Mayo Clinic Biobank (MCB) were genotyped to determine the frequency of the G84E mutation and its association with various cancers. Methods: Subjects were genotyped using a custom TaqMan (Applied Biosystems) assay for G84E (rs138213197). In addition to donating a blood specimen, all MCB participants completed a baseline questionnaire to collect information on medical history and family history of cancer. Results: Forty-nine of 9,012 male patients were carriers of G84E (0.5%). Thirty-one percent (n = 2,595) of participants had been diagnosed with cancer, including 51.1% of G84E carriers compared with just 30.6% of noncarriers (P = 0.004). G84E was most frequently observed among men with prostate cancer compared with men without cancer (P &lt; 0.0001). However, the mutation was also more commonly observed in men with bladder cancer (P = 0.06) and leukemia (P = 0.01). G84E carriers were more likely to have a positive family history of prostate cancer in a first-degree relative compared to noncarriers (36.2% vs. 16.0%, P = 0.0003). Conclusions: Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer. Future investigation is warranted to confirm these associations in order to improve our understanding of the role of germline HOXB13 mutations in human cancer. Impact: The associations between HOXB13 and prostate, leukemia, and bladder suggest that this gene is important in carcinogenesis. Cancer Epidemiol Biomarkers Prev; 24(9); 1366–72. ©2015 AACR.
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
Hasanali, Zainul S. , Saroya, Bikramajit Singh, Stuart, August, Shimko, Sara, Evans, Juanita, Sharma, Kamal Kant , Leshchenko, Violetta V. , Parekh, Samir , Loughran, Thomas P. , Epner, Elliot, Vinod Shah, Mithun, Shah, Meera , Parekh, Samir

Science Translational Medicine | June 24, 2015 | Volume: 7 | Issue: 293 | Pages: No page available

10.1126/scitranslmed.aaa5079 | PMID 26109102 Get It

Epigenetic drugs can overcome resistance to monoclonal antibodies in T-PLL and activate therapeutic targets for antibody-drug conjugates.
Enteropathy‐associated T‐cell lymphoma in the US: higher incidence and poorer survival among Asians
Karanam, Pawan Kumar, Al‐Hamadani, Mohammed , Go, Ronald S.

British Journal of Haematology | June 24, 2015 | Volume: 172 | Issue: 6 | Pages: 990-992

10.1111/bjh.13555 | PMID 26104061 Get It

A new scoring system for predicting survival in patients with non‐small cell lung cancer
Tan, Angelina D., Wampfler, Jason A. , Ross, Helen J. , Sloan, Jeff A. , Schild, Steven E. , Yang, Ping

Cancer Medicine | June 24, 2015 | Volume: 4 | Issue: 9 | Pages: 1334-1343

10.1002/cam4.479 | PMID 26108458 Get It

AbstractThis analysis was performed to create a scoring system to estimate the survival of patients with non‐small cell lung cancer (NSCLC). Data from 1274NSCLCpatients were analyzed to create and validate a scoring system. Univariate (UV) and multivariate (MV) Cox models were used to evaluate the prognostic importance of each baseline factor. Prognostic factors that were significant on bothUVandMVanalyses were used to develop the score. These included quality of life, age, performance status, primary tumor diameter, nodal status, distant metastases, and smoking cessation. The score for each factor was determined by dividing the 5‐year survival rate (%) by 10 and summing these scores to form a total score.MVmodels and the score were validated using bootstrapping with 1000 iterations from the original samples. The score for each prognostic factor ranged from 1 to 7 points with higher scores reflective of better survival. Total scores (sum of the scores from each independent prognostic factor) of 32–37 correlated with a 5‐year survival of 8.3% (95%CI = 0–17.1%), 38–43 correlated with a 5‐year survival of 20% (95%CI = 13–27%), 44–47 correlated with a 5‐year survival of 48.3% (95%CI = 41.5–55.2%), 48–49 correlated to a 5‐year survival of 72.1% (95%CI = 65.6–78.6%), and 50–52 correlated to a 5‐year survival of 84.7% (95%CI = 79.6–89.8%). The bootstrap method confirmed the reliability of the score. Prognostic factors significantly associated with survival on bothUVandMVanalyses were used to construct a valid scoring system that can be used to predict survival ofNSCLCpatients. Optimally, this score could be used when counseling patients, and designing future trials.